AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20630667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver measurements
Number of subjects: 40
Study 18824461 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 1189
Study 18824461 — intervention group
Group type: COMPARATOR
Intervention: Selective invasive strategy
Number of subjects: 1189
Study 18824461 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital revascularization
Number of subjects: 1189
Study 16728246 — intervention group
Group type: EXPERIMENTAL
Intervention: New resin based obturation material with lateral condensation
Number of subjects: 80
Study 16728246 — intervention group
Group type: EXPERIMENTAL
Intervention: New resin based obturation material with continuous wave obturation
Number of subjects: 80
Study 16728246 — intervention group
Group type: COMPARATOR
Intervention: Gutta‐percha with lateral condensation
Number of subjects: 80
Study 16728246 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta‐percha with continuous wave obturation
Number of subjects: 80
Study 14732409 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjacent syllable patterns in speech streams
Number of subjects: 0
Study 14732409 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjacent consonants and vowels with unrelated intervening segments
Number of subjects: 0
Study 11208851 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Number of subjects: 287
Study 11208851 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 8 mg
Number of subjects: 287
Study 11208851 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate 90 mg
Number of subjects: 287
Study 9509896 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-platelet treatment with dipyridamole
Number of subjects: 0
Study 9509896 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 8311489 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS16949A 4 mg single dose
Number of subjects: 0
Study 8311489 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS16949A 8 mg single dose
Number of subjects: 0
Study 8311489 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS16949A 1 mg/day for 3 days (multiple administration)
Number of subjects: 0
Study 8311489 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS16949A 1 mg/day (after doubling the group size from 3 to 6 patients)
Number of subjects: 0
Study 8311489 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS16949A 2 mg/day (multiple administration)
Number of subjects: 0
Study 8311489 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS16949A 4 mg/day (multiple administration)
Number of subjects: 0
Study 8311489 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS16949A 8 mg/day (multiple administration)
Number of subjects: 0
Study 8311489 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS16949A 16 mg/day (multiple administration)
Number of subjects: 0
Study 8311489 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS16949A (multiple administration)
Number of subjects: 0
Study 2898696 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intramuscular injection of phenobarbitone (3.5 mg/kg)
Number of subjects: 48
Study 2898696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29472356 — intervention group
Group type: EXPERIMENTAL
Intervention: B-cell receptorhigh signature
Number of subjects: 83
Study 29472356 — intervention group
Group type: EXPERIMENTAL
Intervention: High (>30%) Ki-67 staining
Number of subjects: 83
Study 29472356 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-gene signature related to B-cell receptor pathway
Number of subjects: 83
Study 28327934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day
Number of subjects: 71
Study 28327934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 400 mg/day
Number of subjects: 71
Study 28327934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 71
Study 28327934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 26276968 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg weekly for 12 weeks
Number of subjects: 0
Study 26276968 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study 26276968 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 0
Study 23701382 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mm Hg LBPP
Number of subjects: 15
Study 23701382 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mm Hg LBPP
Number of subjects: 15
Study 21968445 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrovax(®) vaccine
Number of subjects: 361
Study 21968445 — intervention group
Group type: COMPARATOR
Intervention: TETRAct-Hib(®) vaccine
Number of subjects: 361
Study 19917097 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (techniques chosen by the surgeon)
Number of subjects: 250
Study 19917097 — intervention group
Group type: COMPARATOR
Intervention: Standard non-surgical treatment
Number of subjects: 250
Study 19917097 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (surgical and non-surgical)
Number of subjects: 250
Study 16485576 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved endothelial function group (n = 10)
Number of subjects: 20
Study 16485576 — intervention group
Group type: COMPARATOR
Intervention: Endothelial dysfunction group (n = 10)
Number of subjects: 20
Study 15273013 — intervention group
Group type: EXPERIMENTAL
Intervention: Entity theorists (believing traits are immutable)
Number of subjects: 0
Study 15273013 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental theorists (believing traits are malleable)
Number of subjects: 0
Study 10647074 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 159
Study 10647074 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 159
Study 10647074 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 159
Study 10647074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 9526175 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose solution containing 2g carnitine (Group B)
Number of subjects: 25
Study 9526175 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose‐enriched solution (Group A)
Number of subjects: 25
Study 2202547 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg atenolol and 20 mg nifedipine (1 capsule once daily)
Number of subjects: 16
Study 2202547 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg atenolol and 20 mg nifedipine (2 capsules once daily)
Number of subjects: 16
Study 2202547 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg atenolol and 20 mg nifedipine (1 capsule or 2 capsules once daily)
Number of subjects: 16
Study 6783979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration of 800 mg valproate
Number of subjects: 0
Study 31532044 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa stem meal (MSM) at 100 g/kg
Number of subjects: 1008
Study 31532044 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa stem meal (MSM) at 60 g/kg or less
Number of subjects: 1008
Study 31532044 — intervention group
Group type: COMPARATOR
Intervention: Moringa stem meal (MSM) at 0 g/kg (control)
Number of subjects: 1008
Study 30640284 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 3 months
Number of subjects: 16
Study 30640284 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 16
Study 27727445 — intervention group
Group type: EXPERIMENTAL
Intervention: Advair Diskus 100/50
Number of subjects: 0
Study 27727445 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-way crossover design
Number of subjects: 0
Study 25408262 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of erlotinib 150 mg
Number of subjects: 46
Study 25408262 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of erlotinib 150 mg
Number of subjects: 46
Study 25408262 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A2*1M genotype
Number of subjects: 46
Study 23886915 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity statin therapy (rosuvastatin 40 mg or atorvastatin 80 mg)
Number of subjects: 1039
Study 21466699 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised e‐health support intervention
Number of subjects: 39
Study 20351899 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter reminder
Number of subjects: 1397
Study 20351899 — intervention group
Group type: EXPERIMENTAL
Intervention: Email reminder
Number of subjects: 1397
Study 20351899 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1397
Study 16691030 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream (Elidel) applied twice daily for 2 weeks
Number of subjects: 20
Study 16691030 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control applied twice daily for 2 weeks
Number of subjects: 20
Study 15301621 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing target duration
Number of subjects: 0
Study 15301621 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing mask duration
Number of subjects: 0
Study 15301621 — intervention group
Group type: COMPARATOR
Intervention: Lateral inhibition model
Number of subjects: 0
Study 11778974 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP
Number of subjects: 95
Study 11778974 — intervention group
Group type: EXPERIMENTAL
Intervention: MACOP-B
Number of subjects: 95
Study 11778974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment global QoL
Number of subjects: 95
Study 11778974 — intervention group
Group type: COMPARATOR
Intervention: Reference population
Number of subjects: 95
Study 9502601 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 0
Study 9502601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine/sulfadoxine
Number of subjects: 0
Study 9502601 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (in laboratory infections)
Number of subjects: 0
Study 9502601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine/sulfadoxine (in laboratory infections)
Number of subjects: 0
Study 7934970 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox slow release (ACX‐SR, 500 mg)
Number of subjects: 20
Study 7934970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3154706 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100 mg twice daily)
Number of subjects: 8
Study 3154706 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg three times a day) plus Metoprolol (100 mg twice daily)
Number of subjects: 8
Study 3154706 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg twice daily) plus Metoprolol (100 mg twice daily)
Number of subjects: 8
Study 3154706 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil and Nitrendipine
Number of subjects: 8
Study 29084372 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg of HGF per vocal fold
Number of subjects: 18
Study 29084372 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 μg of HGF per vocal fold
Number of subjects: 18
Study 29084372 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg of HGF per vocal fold
Number of subjects: 18
Study 29084372 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study 27411000 — intervention group
Group type: EXPERIMENTAL
Intervention: 1st-person point of view narrative
Number of subjects: 0
Study 27411000 — intervention group
Group type: COMPARATOR
Intervention: 3rd-person point of view narrative
Number of subjects: 0
Study 27411000 — intervention group
Group type: EXPERIMENTAL
Intervention: Similar protagonist (young, same sex)
Number of subjects: 0
Study 27411000 — intervention group
Group type: COMPARATOR
Intervention: Dissimilar protagonist (older, opposite sex)
Number of subjects: 0
Study 27411000 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referencing
Number of subjects: 0
Study 27411000 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility and severity perceptions
Number of subjects: 0
Study 23930950 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (10⁹ colony-forming units twice daily; n=20)
Number of subjects: 39
Study 23930950 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=19)
Number of subjects: 39
Study 24161011 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic computer‐assisted navigation (group I: 75 patients, 80 knees)
Number of subjects: 151
Study 24161011 — intervention group
Group type: COMPARATOR
Intervention: Without electromagnetic computer‐assisted navigation (group II: 76 patients, 80 knees)
Number of subjects: 151
Study 20500318 — intervention group
Group type: EXPERIMENTAL
Intervention: Single application of lidocaine (one application five minutes prior to catheterisation)
Number of subjects: 200
Study 20500318 — intervention group
Group type: COMPARATOR
Intervention: Two applications of lidocaine (two applications spaced five minutes apart prior to catheterisation)
Number of subjects: 200
Study 20500318 — intervention group
Group type: EXPERIMENTAL
Intervention: Single application of lidocaine
Number of subjects: 200
Study 20500318 — intervention group
Group type: COMPARATOR
Intervention: Two applications of lidocaine
Number of subjects: 200
Study 18793340 — intervention group
Group type: EXPERIMENTAL
Intervention: True eradication therapy
Number of subjects: 183
Study 18793340 — intervention group
Group type: COMPARATOR
Intervention: Placebo eradication therapy
Number of subjects: 183
Study 16885070 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 790
Study 16885070 — intervention group
Group type: COMPARATOR
Intervention: Control (no abciximab)
Number of subjects: 790
Study 14648521 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose and non‐nutritive sucking (NNS)
Number of subjects: 190
Study 14648521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose alone
Number of subjects: 190
Study 14648521 — intervention group
Group type: COMPARATOR
Intervention: Sterile water and NNS (control)
Number of subjects: 190
Study 10820932 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated streptokinase infusion over 15 minutes (group 1, n = 24)
Number of subjects: 47
Study 10820932 — intervention group
Group type: COMPARATOR
Intervention: Conventional streptokinase infusion over one hour (group 2, n = 23)
Number of subjects: 47
Study 8648213 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral doses of Ty800 (10^7, 10^8, 10^9, or 10^10 cfu)
Number of subjects: 11
Study 8648213 — intervention group
Group type: COMPARATOR
Intervention: Control vaccinees received 4 oral doses of S. typhi Ty21a
Number of subjects: 11
Study 7645789 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam plus fentanyl
Number of subjects: 207
Study 7645789 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 207
Study 3536031 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine impregnated dressing (Inadine)
Number of subjects: 0
Study 3536031 — intervention group
Group type: COMPARATOR
Intervention: Standard petroleum jelly gauze dressing
Number of subjects: 0
Study 29287237 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of essential oil
Number of subjects: 34
Study 29287237 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of perfume
Number of subjects: 34
Study 27217266 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentoring intervention (2 in-person sessions and 5 phone calls over 10 weeks)
Number of subjects: 460
Study 27217266 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (didactic sessions on avoiding HIV transmission)
Number of subjects: 460
Study 24893862 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight control intervention
Number of subjects: 118
Study 23844489 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis combined with stretching exercise
Number of subjects: 30
Study 23844489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound combined with stretching exercise
Number of subjects: 30
Study 23844489 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercise
Number of subjects: 30
Study 20724597 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting Cdc7 with RNAi
Number of subjects: 0
Study 20724597 — intervention group
Group type: COMPARATOR
Intervention: Cdc7 kinase activity recovery in untransformed breast epithelial cells
Number of subjects: 0
Study 20724597 — intervention group
Group type: COMPARATOR
Intervention: Increased Cdc7 expression
Number of subjects: 0
Study 18717717 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the primary motor cortex (M1)
Number of subjects: 20
Study 18717717 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 20
Study 18717717 — intervention group
Group type: COMPARATOR
Intervention: Occipital cortex (V1) stimulation
Number of subjects: 20
Study 18717717 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study 16470242 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support and educational materials from oncology nurses
Number of subjects: 77
Study 16470242 — intervention group
Group type: COMPARATOR
Intervention: Educational materials only (Control)
Number of subjects: 77
Study 12499327 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI dietary advice
Number of subjects: 104
Study 12499327 — intervention group
Group type: COMPARATOR
Intervention: Traditional carbohydrate-exchange dietary advice (CHOx)
Number of subjects: 104
Study 11030499 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching intervention (30 minutes of daily stretching into dorsiflexion with a torque of 7.5 N x m for 4 weeks)
Number of subjects: 14
Study 11030499 — intervention group
Group type: COMPARATOR
Intervention: Control (no stretches on contralateral ankles)
Number of subjects: 14
Study 8800496 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma content of vitamin E
Number of subjects: 406
Study 8800496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid standardised vitamin E
Number of subjects: 406
Study 1531200 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a
Number of subjects: 30
Study 1531200 — intervention group
Group type: COMPARATOR
Intervention: Control (no GnRH‐a)
Number of subjects: 30
Study 6400113 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restriction for eight weeks
Number of subjects: 18
Study 6400113 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 18
Study 30879820 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted alfalfa hay (RAH)
Number of subjects: 20
Study 30879820 — intervention group
Group type: COMPARATOR
Intervention: Dry alfalfa hay (AH)
Number of subjects: 20
Study 29499722 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics and regular clinical assessment
Number of subjects: 0
Study 29499722 — intervention group
Group type: COMPARATOR
Intervention: Appendicectomy
Number of subjects: 0
Study 26806141 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual assessment with traditional treatment
Number of subjects: 84
Study 26806141 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment only (Control)
Number of subjects: 84
Study 25332329 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat group (pureed meats)
Number of subjects: 42
Study 25332329 — intervention group
Group type: COMPARATOR
Intervention: Cereal group (infant cereal)
Number of subjects: 42
Study 22872029 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycaemic Load (HGL): 7g protein, 9g fat, 50g carbohydrate, GL 33
Number of subjects: 39
Study 22872029 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Glycaemic Load (MGL): 14g protein, 9g fat, 45g carbohydrate, GL 24
Number of subjects: 39
Study 22872029 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycaemic Load (LGL): 18g protein, 10g fat, 38g carbohydrate, GL 18
Number of subjects: 39
Study 22872029 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 39
Study 20461799 — intervention group
Group type: EXPERIMENTAL
Intervention: ParkinsonNet intervention (implemented in 8 experimental regions)
Number of subjects: 699
Study 20461799 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, 8 regions with unchanged organization of care)
Number of subjects: 699
Study 17904226 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 516
Study 17904226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study 15764762 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 15
Study 15764762 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 15
Study 15764762 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg)
Number of subjects: 15
Study 15764762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12352386 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 1112
Study 10100058 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm position on the arm-rest of the chair
Number of subjects: 69
Study 10100058 — intervention group
Group type: COMPARATOR
Intervention: Arm position at the level of the mid-sternum (right atrial level)
Number of subjects: 69
Study 7768272 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg glyburide
Number of subjects: 6
Study 7768272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2221162 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine and individual psychotherapy
Number of subjects: 28
Study 2221162 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus psychotherapy
Number of subjects: 28
Study 1127891 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive model
Number of subjects: 120
Study 1127891 — intervention group
Group type: EXPERIMENTAL
Intervention: Altruistic model
Number of subjects: 120
Study 1127891 — intervention group
Group type: COMPARATOR
Intervention: Different treatment conditions
Number of subjects: 120
Study 1127891 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive or altruistic behavior in the first situation
Number of subjects: 120